SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) today announced that a team of researchers at the Fraunhofer Institute in Germany is using Affymetrix’ Whole Transcript (WT) gene expression technology to better understand the molecular basis of drug-induced liver injury (DILI). The ultimate goal of the project is to develop a diagnostic array that can detect signals of liver toxicity earlier and more accurately than traditional techniques.
